

Include 3 bullets (< 30 words total) per slide – the most important messages associated with the particular slide

Team name: AqueousJoint

Date updated: 20/09/21

S1: Title & Elevator Pitch/Headline	<ul style="list-style-type: none"> • Revolutionizing biolubrication • Imagine that we could relieve the pain of patients with joint disorders by locally injecting our lubricant that coats and protects cartilage to enable smooth articulation. • AqueousJoint
S2: The problem and who has it	<ul style="list-style-type: none"> • More than 300M people globally suffer from Osteoarthritis, a cartilage disorder • Articulation of unprotected, damaged cartilage leads to pain for the patient • Unable to maintain active lifestyle
S3: The solution	<ul style="list-style-type: none"> • Mechanical protection of cartilage surfaces • by directly applying a robust, long-lasting boundary lubricant that resists high loads and shear forces • anticipated to lead to less pain by restoring natural lubrication
S4: Product (how it addresses the problem)	<ul style="list-style-type: none"> • AqueousJoint developed as an intra-articular knee injectable to treat mild/moderate OA • Anticipated patient benefits: reducing pain, delaying surgery, improving dosing schedule
S5: Technology	<ul style="list-style-type: none"> • AJ composed of elastic, lipid-based spheres that are stabilized by a highly hydrated polymer • Adsorb to surface • Hold hydration water in the most efficient way, water is the lubricating element
S6: Competing approaches	<ul style="list-style-type: none"> • Hyaluronic acid, corticosteroids and biologics injectables • HA dominates market, GAM > 3Bn anticipated to grow at ~10% CAGR • HA: viscous supplement, different MOA, shorter retention time
S7: Traction	<ul style="list-style-type: none"> • Funding through governmental and private investors • LIPO holds exclusive IP license covering 7 patents to commercialize its unique biolubricants • Under feasibility study with commercial partner to co-develop an innovative Dry Eye solution • Strong interest from 2 medtech players to sublicense AJ for commercialization
S8: Team	<ul style="list-style-type: none"> • Founders team worked together as scientists before spinning out the technology • Currently 14 FTE with strong expertise in quality assurance, product development, BD, management and clinical matters • Supported by highly experienced advisory
S9: Closing Why AqueousJoint?	<ul style="list-style-type: none"> • Lubrication capability outperforms HA by 2 orders of magnitude at 10x higher pressures • + retention time in joint cavity >50x longer than market standard HA • Shows its disruptive potential